대한의생명과학회지 (Biomedical Science Letters)

  • 제29권4호
  • /
  • Pages.371-375
  • /
  • 2023
  • /
  • 1738-3226(pISSN)
  • /
  • 2288-7415(eISSN)
대한의생명과학회 (The Korean Society for Biomedical Laboratory Sciences)
권호 표지
DOI QR코드

DOI QR Code

Vemurafenib Enhances NK cell Expansion and Tumor-killing Activity for Cancer Immunotherapy

  • Min Hwa Shin (Immune Research Institute, Seegene Medical Foundation)
  • 투고 : 2023.11.26
  • 심사 : 2023.12.12
  • 발행 : 2023.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Natural killer (NK) cells are innate immune cells and play important roles as the first immune cells to recognize and kill cancer. In patients with advanced and terminal cancer, NK cells are often inactivated, suggesting that NK cells may play important roles in cancer treatment. In particular, the proportion of NK cells among immune cells infiltrating tumor tissues is often low, which suggests that NK cells do not survive in tumor microenvironment (TME). In order to overcome these hurdles of NK cells in cancer treatment, it is critical to develop strategies that enhance the proliferation and cytolytic activity of NK cells. We applied Vemurafenib to NK cells and measured the degree of NK cell proliferation and functional activation. We obtained unexpected results of increased NK cell numbers and anti-tumor activity after Vemurafenib treatment. Although further investigation is required to uncover the detailed mechanisms, our results suggest that Vemurafenib is a promising candidate to increase the efficacy of cancer immunotherapy using NK cells.

키워드

참고문헌

  1. Ascierto PA, Kirkwood JM, Grob J-J, Simeone E, Grimaldi AM, Maio M, Palmieri G, Testori A, Marincola FM, Mozzillo N. The role of braf v600 mutation in melanoma. Journal of Translational Medicine. 2012. 10: 85. 
  2. Beck D, Niessner H, Smalley KS, Flaherty K, Paraiso KH, Busch C, Sinnberg T, Vasseur S, Iovanna JL, Driessen S, Stork B, Wesselborg S, Schaller M, Biedermann T, Bauer J, Lasithiotakis K, Weide B, Eberle J, Schittek B, Schadendorf D, et al. Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in brafv600e melanoma cells. Sci Signal. 2013. 6: ra7. 
  3. Berrien-Elliott MM, Jacobs MT, Fehniger TA. Allogeneic natural killer cell therapy. Blood. 2023. 141: 856-868. 
  4. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, et al. Mutations of the braf gene in human cancer. Nature. 2002. 417: 949-954.  https://doi.org/10.1038/nature00766
  5. Kim G, McKee AE, Ning Y-M, Hazarika M, Theoret M, Johnson JR, Xu QC, Tang S, Sridhara R, Jiang X, He K, Roscoe D, McGuinn WD, Helms WS, Russell AM, Miksinski SP, Zirkelbach JF, Earp J, Liu Q, Ibrahim A, et al. Fda approval summary: Vemurafenib for treatment of unresectable or metastatic melanoma with the brafv600e mutation. Clinical Cancer Research. 2014. 20: 4994-5000.  https://doi.org/10.1158/1078-0432.CCR-14-0776
  6. Lim SA, Moon Y, Shin MH, Kim TJ, Chae S, Yee C, Hwang D, Park H, Lee KM. Hypoxia-driven hif-1α activation reprograms pre-activated nk cells towards highly potent effector phenotypes via erk/stat3 pathways. Cancers (Basel). 2021. 13. 
  7. Prager I, Watzl C. Mechanisms of natural killer cell-mediated cellular cytotoxicity. J Leukoc Biol. 2019. 105: 1319-1329.  https://doi.org/10.1002/JLB.MR0718-269R
  8. Ramirez-Labrada A, Pesini C, Santiago L, Hidalgo S, Calvo-Perez A, Onate C, Andres-Tovar A, Garzon-Tituana M, Uranga-Murillo I, Arias MA, Galvez EM, Pardo J. All about (nk cellmediated) death in two acts and an unexpected encore: Initiation, execution and activation of adaptive immunity. Frontiers in Immunology. 2022. 13. 
  9. Sanchez JN, Wang T, Cohen MS. Braf and mek inhibitors: Use and resistance in braf-mutated cancers. Drugs. 2018. 78: 549-566.  https://doi.org/10.1007/s40265-018-0884-8
  10. Shin MH, Kim J, Lim SA, Kim J, Kim SJ, Lee KM. Nk cell-based immunotherapies in cancer. Immune Netw. 2020. 20: e14.
  11. Shin MH, Oh E, Kim Y, Nam DH, Jeon SY, Yu JH, Minn D. Recent advances in car-based solid tumor immunotherapy. Cells. 2023. 12. 
  12. Swaika A, Crozier JA, Joseph RW. Vemurafenib: An evidence-based review of its clinical utility in the treatment of metastatic melanoma. Drug Des Devel Ther. 2014. 8: 775-787.  https://doi.org/10.2147/DDDT.S31143
  13. Wolf NK, Kissiov DU, Raulet DH. Roles of natural killer cells in immunity to cancer, and applications to immunotherapy. Nature Reviews Immunology. 2023. 23: 90-105.  https://doi.org/10.1038/s41577-022-00732-1
  14. Zhou Y, Cheng L, Liu L, Li X. Nk cells are never alone: Crosstalk and communication in tumour microenvironments. Mol Cancer. 2023. 22: 34.